Simpler, more portable ECGs: Emory experts hosting computing challenge

Emory biomedical informatics specialists are hosting an international computing contest to support simpler, more potable electrocardiogram Read more

First (and massive) whole-genome study of IBD in African Americans

In African Americans, the genetic risk landscape for inflammatory bowel disease (IBD) is very different from that of people with European ancestry, according to results of the first whole-genome study of IBD in African Americans. The authors say that future clinical research on IBD needs to take ancestry into account. Findings of the multi-center study, which analyzed the whole genomes of more than 1,700 affected individuals with Crohn’s disease and ulcerative colitis and more than Read more

Emory researchers SNARE new Alzheimer’s targets

Diving deep into Alzheimer’s data sets, a recent Emory Brain Health Center paper in Nature Genetics spots several new potential therapeutic targets, only one of which had been previous linked to Alzheimer’s. The Emory analysis was highlighted by the Alzheimer’s site Alzforum, gathering several positive comments from other researchers. Thomas Wingo, MD Lead author Thomas Wingo and his team -- wife Aliza Wingo is first author – identified the targets by taking a new approach: tracing Read more

statistics

A push for reproducibility in biomedical research

Editor’s note: guest post from Neuroscience graduate student Erica Landis.

Neuroscience graduate student Erica Landis

Evidence is increasing that lack of reproducibility, whatever the cause, is a systemic problem in biomedical science. While institutions like the NIH and concerned journal editors are making efforts to implement more stringent requirements for rigorous and reproducible research, scientists themselves must make conscious efforts to avoid common pitfalls of scientific research. Here at Emory, several scientists are making greater efforts to push forward to improve scientific research and combat what is being called “the reproducibility crisis.”

In 2012, C. Glenn Begley, then a scientist with the pharmaceutical company Amgen, published a commentary in Nature on his growing concern for the reproducibility of preclinical research. Begley and his colleagues had attempted to replicate 53 published studies they identified as relevant to their own research into potential pharmaceuticals. They found that only 6 of the 53 publications could be replicated; even with help from the original authors. Similar studies have consistently found that greater than 50 percent of published studies could not be replicated. This sparked a period of great concern and questioning for scientists. It seemed to Begley and others that experimenter bias, carelessness, poor understanding of statistics, and the career-dependent scramble to publish contributes to a misuse of the scientific method. These factors contribute to what is now called the reproducibility crisis. In April 2017, Richard Harris published Rigor Mortis, a survey of the problem in preclinical research, which has kept the conversation going and left many wondering what the best solution to these issues could be. To combat the reproducibility crisis, Harris argues that funding agencies, journal editors and reviewers, research institutions, and scientists themselves all have a role to play.

Read more

Posted on by Quinn Eastman in Uncategorized Leave a comment